文献速递儿童神经与发育行为

哌甲酯与行为父母训练治疗3-5岁注意缺陷多动障碍儿童的随机双盲安慰剂和假行为父母训练对照试验

Efficacy and safety of methylphenidate and behavioural parent training for children aged 3-5 years with attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled, and sham behavioural parent training-controlled trial.
PubMed 文献 · Lancet Child Adolesc Health · 2022-10-26

该研究在巴西圣保罗对153名3-5岁中重度ADHD儿童进行8周随机双盲安慰剂和假行为父母训练对照试验,发现哌甲酯可减少ADHD症状并改善功能,行为父母训练可改善功能。

要点

  • 哌甲酯在减少ADHD症状和改善功能方面优于安慰剂加教育干预。
  • 行为父母训练在改善整体功能方面优于安慰剂加教育干预,但对症核心状改善无统计学意义。
  • 哌甲酯组轻度不良事件更多,但中重度不良事件无组间差异。

核心结论

  • 哌甲酯能有效减少ADHD症状并改善功能,行为父母训练能改善功能,均针对3-5岁ADHD儿童8周治疗。

研究设计与样本

  • 8周随机双盲安慰剂对照和假行为父母训练对照临床试验(MAPPA研究),在巴西圣保罗大学医学院精神病学研究所进行。
  • 纳入153名3-5岁中重度ADHD儿童,按1:1:1随机分为哌甲酯加教育干预组、安慰剂加行为父母训练组、安慰剂加教育干预组,每组51人。
  • 主要结局为父母和教师版SNAP-IV量表复合评分、临床总体印象严重程度量表(CGI-S)和儿童总体评估量表(CGAS)。

主要发现

  • 哌甲酯加教育干预组与安慰剂加行为父母训练组在主要结局上无统计学或临床显著差异。
  • 哌甲酯加教育干预组轻度不良事件多于其他两组,中重度不良事件无组间差异。

关键数值与推荐

  • 行为父母训练和教育干预为每周一次90分钟会谈,持续8周。
  • 主要结局包括SNAP-IV-P/T、CGI-S和CGAS评分。

临床怎么用

  • 对于3-5岁中重度ADHD儿童,哌甲酯可考虑用于减少症状和改善功能,但需监测轻度不良事件。
  • 行为父母训练可作为改善整体功能的干预选项,尽管对核心症状改善不显著。
  • 哌甲酯与行为父母训练在主要结局上无显著差异,治疗选择需结合个体情况。

局限性

  • 研究仅持续8周,长期疗效和安全性未报告。
  • 样本来自单一中心巴西圣保罗,结果外推需谨慎。
  • 开放观察性随访仍在进行中,长期数据待报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is insufficient evidence to support treatment recommendations for preschool children aged 3-5 years with attention-deficit hyperactivity disorder (ADHD). We aimed to investigate the efficacy and safety of methylphenidate and behavioural parent training in reducing the frequency and severity of symptoms and improving global functioning in preschool children with ADHD. METHODS: We did an 8-week, randomised, double-blind, placebo-controlled and sham behavioural parent training-controlled clinical trial (the MAPPA Study) in children aged 3-5 years with moderate-to-severe ADHD. The trial was conducted at the Institute of Psychiatry, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, Brazil. Participants were randomly assigned (1:1:1) to receive immediate-release methylphenidate plus educational intervention (sham behavioural parent training), placebo medication plus behavioural parent training, or placebo medication plus educational intervention. Randomisation was done by an independent research manager by use of a permuted block randomisation procedure. Parents, teachers, study staff, and evaluators remained masked to group allocation. Methylphenidate and placebo were titrated to a maximum dose of 1·25 mg/kg per day administered orally twice daily, and behavioural parent training and the educational intervention were delivered weekly through 90 min sessions with both the child and parent, conducted by two psychologists or learning therapists. The primary outcomes were parents' and teachers' composite scores of the Swanson, Nolan, and Pelham-IV scale (SNAP-IV-P/T), the Clinical Global Impressions Severity (CGI-S) scale, and the Children's Global Assessment Scale (CGAS). This trial is registered with ClinicalTrials.gov, NCT02807870, and is now complete. All participants were invited to participate in an open observational follow-up, which is ongoing. FINDINGS: Between Aug 21, 2016, and Oct 21, 2019, 153 children were randomly assigned to receive methylphenidate plus the educational intervention (n=51), placebo plus behavioural parent training (n=51), or placebo plus the educational intervention (n=51). Nine (6%) children discontinued treatment. All participants were included in the intention-to-treat analysis. Children in the methylphenidate plus educational intervention group showed greater reductions in the SNAP-IV-P/T (endpoint mean difference -3·93 [95% CI -7·14 to -0·73], p=0·049; effect size -0·55 [95% CI -0·99 to -0·10]) and CGI-S scores (endpoint mean difference -0·49 [-0·82 to -0·17], p=0·0088; effect size -0·70 [-1·16 to -0·24]) and a greater increase in CGAS scores (endpoint mean difference 5·25 [95% CI 2·09 to 8·40], p=0·0036; effect size 0·80 [95% CI 0·32 to 1·28]) than children in the placebo plus educational intervention group. Children in the placebo plus behavioural parent training group did not have significantly different SNAP-IV-P/T scores (endpoint mean difference -3·18 [95% CI -6·38 to 0·02], p=0·077; effect size -0·44 [95% CI -0·89 to 0·003]) or CGI-S scores (endpoint mean difference -0·35 [-0·68 to -0·03], p=0·052; effect size -0·50 [-0·96 to -0·04]) compared to children in the placebo plus educational intervention group, but they had a greater increase in CGAS scores compared to the placebo plus educational intervention group (endpoint mean difference 3·69 [0·53 to 6·85], p=0·033; effect size 0·56 [0·08 to 1·04]). Children in the methylphenidate plus educational intervention versus placebo plus behavioural parent training group did not have statistically or clinically significant differences in primary outcomes. Children in the methylphenidate plus educational intervention group had more mild adverse events than the other two groups, and there were no between-group differences for moderate or severe adverse events. INTERPRETATION: Methylphenidate was effective in reducing ADHD symptoms and improving functionality, and behavioural parent training was effective in improving functionality for preschool children with ADHD after 8 weeks of treatment. FUNDING: São Paulo Research Foundation and Brazilian National Council for Scientific and Technological Development.

来源:Lancet Child Adolesc Health,查看原文。版权归原作者所有。

引用

  1. Sugaya LS, Salum GA, de Sousa Gurgel W, et al. Efficacy and safety of methylphenidate and behavioural parent training for children aged 3-5 years with attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled, and sham behavioural parent training-controlled trial. Lancet Child Adolesc Health. 2022. PMID: 36306807. doi:10.1016/S2352-4642(22)00279-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。